No abstract available.
Congenital Abnormalities* ; Humans ; Orthognathic Surgery* ; Psychological Tests*

PURPOSE: Recent studies have demonstrated and suggested that Interleukin (IL) -10 and IL-11 are implicated in the pathophysiology of RSV infection and may act in the regulation of inflammatory response. We measured IL-10 and IL-11 in nasal secretions of infants with acute RSV bronchiolitis to investigate if there is any difference in the production of these anti-inflammatory cytokines between atopic and non-atopic subjects. METHODS: We measured IL-10, IL-11 in nasal secretions of 44 infants (20 were atopic) with acute RSV bronchiolitis. The nasal secretion samples were obtained from patients on admission and stored immediately at -70degrees C until analysis. Atopy was defined as having at least one positive skin prick test to common allergens, a positive history of atopic dermatitis or age-matched, high serum IgE level. RESULTS: IL-10 and IL-11 increased significantly in nasal secretion of infants with acute RSV bronchiolitis. Both IL-10 and IL-11 were significantly lower in atopic patients than in non-atopic patients. There was no significant relation between the severity of symptoms and IL-10 or IL-11 levels. CONCLUSION: Our study showed that both IL-10 and IL-11 increased in nasal secretion during acute RSV bronchiolitis, and the levels were significantly lower in atopic patients than in non-atopic patients. It suggests that the airway inflammation induced by RSV may be different between atopic and non-atopic patients and this may be associated with lower induction of these anti-inflammatory cytokines in atopic patients.
Allergens ; Bronchiolitis* ; Cytokines* ; Dermatitis, Atopic ; Humans ; Immunoglobulin E ; Infant ; Inflammation ; Interleukin-10 ; Interleukin-11 ; Interleukins ; Respiratory Syncytial Viruses* ; Skin

BACKGROUND: Granisetron, a new 5-HT3 receptor antagonist, was reported as a highly effective antiemetics, especially in combination with dexamethasone, in the prevention of acute emesis induced by cisplatin. But there is lack of data about effectiveness in the prevention of delayed emesis. In this study, the efficacy of granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin was evaluated. MATERIALS AND METHODS: Sixty-four patients who were to receive high-dose cisplatin containing chemotherapy regimen were enrolled in this study. They were received 20 mg of dexamethasone and 3 mg of granisetron at 30 min and 10 minutes prior to cisplatin infusion, respectively. They were monitored for 5 days, first 24 hours for acute nausea/ vomiting and the subsequent 4 days for delayed nausea/vomiting. Antiemetic effect of granisetron was evaluated according to the criteria of Italian Group of Antiemetic Research. RESULTS: Control of delayed nausea and vomiting was achieved in 58% and 84%, respectively. Eastern Cooperative Oncology Group performance status was a statistically significant prognostic factor for control of acute vomiting and delayed nausea/vomiting. There were no stastically significant differences between control of delayed nausea/ vomiting and other prognostic factors, including sex, age, and prior history of cisplatin therapy. The antiemetic effect was greater in the patients who had controled acute nausea/ vomiting than those who had not. CONCLUSION: Granisetron plus dexamethasone is an excellent regimen in the control of not only acute emesis but also delayed emesis induced by high-dose cisplatin chemotherapy.
Antiemetics ; Cisplatin ; Dexamethasone* ; Drug Therapy ; Granisetron* ; Humans ; Nausea* ; Receptors, Serotonin, 5-HT3 ; Serotonin ; Vomiting*